Cerus Corporation CU2.F Stock
Cerus Corporation Price Chart
Cerus Corporation CU2.F Financial and Trading Overview
Cerus Corporation stock price | 1.64 EUR |
Previous Close | 1.53 EUR |
Open | 1.53 EUR |
Bid | 1.56 EUR x 120000 |
Ask | 1.6 EUR x 120000 |
Day's Range | 1.56 - 1.56 EUR |
52 Week Range | 1.55 - 4.65 EUR |
Volume | 4.57K EUR |
Avg. Volume | 225 EUR |
Market Cap | 285.53M EUR |
Beta (5Y Monthly) | 1.056459 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.16 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.4 EUR |
CU2.F Valuation Measures
Enterprise Value | 289.42M EUR |
Trailing P/E | N/A |
Forward P/E | -4.7151513 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1.8609792 |
Price/Book (mrq) | 5.537367 |
Enterprise Value/Revenue | 1.886 |
Enterprise Value/EBITDA | -7.532 |
Trading Information
Cerus Corporation Stock Price History
Beta (5Y Monthly) | 1.056459 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 4.65 EUR |
52 Week Low | 1.55 EUR |
50-Day Moving Average | 2.19 EUR |
200-Day Moving Average | 2.68 EUR |
CU2.F Share Statistics
Avg. Volume (3 month) | 225 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 180.8M |
Float | 158.76M |
Short Ratio | N/A |
% Held by Insiders | 3.08% |
% Held by Institutions | 79.66% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | June 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -33.23% |
Operating Margin (ttm) | -26.75% |
Gross Margin | 55.44% |
EBITDA Margin | -25.042% |
Management Effectiveness
Return on Assets (ttm) | -12.35% |
Return on Equity (ttm) | -79.59% |
Income Statement
Revenue (ttm) | 153.43M EUR |
Revenue Per Share (ttm) | 0.86 EUR |
Quarterly Revenue Growth (yoy) | -5.20% |
Gross Profit (ttm) | 87.09M EUR |
EBITDA | -38424000 EUR |
Net Income Avi to Common (ttm) | -51000000 EUR |
Diluted EPS (ttm) | -0.25 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 84.5M EUR |
Total Cash Per Share (mrq) | 0.47 EUR |
Total Debt (mrq) | 88.01M EUR |
Total Debt/Equity (mrq) | 170.27 EUR |
Current Ratio (mrq) | 2.01 |
Book Value Per Share (mrq) | 0.281 |
Cash Flow Statement
Operating Cash Flow (ttm) | -21310000 EUR |
Levered Free Cash Flow (ttm) | -7756000 EUR |
Profile of Cerus Corporation
Country | Germany |
State | CA |
City | Concord |
Address | 1220 Concord Avenue |
ZIP | 94520 |
Phone | 925 288 6000 |
Website | https://www.cerus.com |
Industry | Medical Devices |
Sector(s) | Healthcare |
Full Time Employees | 665 |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Q&A For Cerus Corporation Stock
What is a current CU2.F stock price?
Cerus Corporation CU2.F stock price today per share is 1.64 EUR.
How to purchase Cerus Corporation stock?
You can buy CU2.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cerus Corporation?
The stock symbol or ticker of Cerus Corporation is CU2.F.
Which industry does the Cerus Corporation company belong to?
The Cerus Corporation industry is Medical Devices.
How many shares does Cerus Corporation have in circulation?
The max supply of Cerus Corporation shares is 184.89M.
What is Cerus Corporation Price to Earnings Ratio (PE Ratio)?
Cerus Corporation PE Ratio is now.
What was Cerus Corporation earnings per share over the trailing 12 months (TTM)?
Cerus Corporation EPS is -0.16 EUR over the trailing 12 months.
Which sector does the Cerus Corporation company belong to?
The Cerus Corporation sector is Healthcare.